01
Cash & equivalents increased 5193.5%
Cash & equivalents changed +5193.5% from the comparable as-filed period.
$10.2M→$540.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTDamora Therapeutics, Inc.'s latest supported as-filed period reports net income of -$31.2M, 807.0% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +5193.5% from the comparable as-filed period.
Net income changed -807.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed -922.9% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
DMRA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-349537SEC ↗10-QAug 10, 2026Period Jun 30, 20260001193125-26-342307SEC ↗8-KJul 20, 2026Period Jul 16, 20260001193125-26-308899SEC ↗4Jul 7, 2026Period Jul 3, 20260001193125-26-297818SEC ↗8-KJun 17, 2026Period Apr 28, 20260001193125-26-274093SEC ↗10-QMay 12, 2026Period Mar 31, 20260001193125-26-219327SEC ↗8-KMay 4, 2026Period Apr 28, 20260001193125-26-203913SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 12, 2026Filed Aug 13, 2026 | Cheng AndrewDirector | Grant Or AwardDirect | 30,350 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +1643.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Stock-based compensation changed +6113.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-163909